Bevacizumab plus fluorouracil: The value of being part of a developing story

Journal of Clinical Oncology

Volumn 23, Issue 16, 2005, Pages 3660-3662

  Sobrero, Alberto ^a   Bruzzi, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; VATALANIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; COLORECTAL TUMOR; METASTASIS; NOTE; SAFETY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; SAFETY;

EID: 20544456390     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.941     Document Type: Editorial

References (15)

1. Mayer RJ: Two steps forward in the treatment of colorectal cancer. N Engl J Med 350:2406-2408, 2004
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
3. Kabbinavar FF, Shulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil/leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23: 10.1200/JCO.2005.05.112
4. Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab prolongs survival in first line colorectal patients: Results of a phase III trial of bevacizumab in combination with bolus IFL as first line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22, 2003 (abstr 3646)
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (5-fluorouracil)/leucovorin (LV) with 5-fluorouracil /LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
6. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979-1986, 2003
7. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
8. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004 [Erratum: Nat Med 10:649, 2004]
9. Fyfe GI, Hurwitz H, Fehrenbacher L, et al: Bevacizumab plus irinotecan 5-fluorouracil/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patients subgroups. Proc Am Soc Clin Oncol 23:274, 2004 (abstr 3617)
10. Sandler AB, Blumenschein GR, Henderson T, et al: Phase I/II trial evaluating the anti VEGF Mab bevacizumab in combination with erlotinib, a HER1 EGFR TK inhibitor, in patients with recurrent non small cell lung cancer. Proc Am Soc Clin Oncol 23:127, 2004 (abstr 2000)
11. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
12. Chen HX, Mooney M, Boron L, et al: Bevacizumab plus 5-fluorouracil /leucovorin for advanced colorectal cancer that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC0301). Proc Am Soc Clin Oncol 23:249, 2004 (abstr 3515)
13. Miller KD, Rugo H, Cobleigh MA, et al: Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76:s37, 2002 (suppl 1)
14. Ellis LM: Antiangiogenic therapy at a crossroads: Clinical trial results and 5-fluorouracil future directions. J Clin Oncol 21:281s-283s, 2003 (suppl 23)
15. Davis DW, McConkey DJ, Abbruzzese JL, et al: Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89:8-14, 2003